Dosing Considerations for Desvenlafaxine in Cirrhotic Patients

Introduction to Hepatic Impairment

The American Association for the Study of Liver Diseases recommends that patients with cirrhosis and hepatic encephalopathy risk should be carefully monitored when using psychoactive medications, such as desvenlafaxine, due to the increased risk of precipitating or worsening hepatic encephalopathy 1

The European Association for the Study of the Liver suggests that close monitoring of renal function, mental status, and clinical response is essential when using psychotropic medications, such as desvenlafaxine, in cirrhotic patients, with frequent clinical assessment necessary given limited safety data in decompensated cirrhosis 2
The Child-Pugh score should be assessed to determine the severity of hepatic impairment, with Child-Pugh A (5-6 points) indicating compensated cirrhosis, Child-Pugh B (7-9 points) indicating moderate hepatic impairment, and Child-Pugh C (10-15 points) indicating severe hepatic impairment, with a maximum dose of 50 mg daily recommended for Child-Pugh B and C patients 2

Benzodiazepines should be used with extreme caution in cirrhotic patients due to risk of precipitating or worsening hepatic encephalopathy 3
Non-steroidal anti-inflammatory drugs (NSAIDs) should be avoided in patients with cirrhosis and ascites due to risk of renal impairment, hyponatremia, and diuretic resistance 4, 5
Angiotensin-converting enzyme inhibitors and angiotensin II antagonists should generally not be used in patients with ascites due to increased risk of renal impairment 4

Monitor renal function, as patients with cirrhosis are at increased risk of hepatorenal syndrome 6

The American Association for the Study of Liver Diseases recommends that all patients with cirrhosis require assessment for hepatic encephalopathy at baseline and with each dose adjustment, as psychoactive medications like mirtazapine increase the risk of precipitating or worsening encephalopathy, with monitoring for precipitating factors including constipation, infection, GI bleeding, electrolyte disturbances, and dehydration 7, 8
The European Association for the Study of the Liver suggests monitoring for transaminase elevations and clinically significant ALT elevations, as well as somnolence, hyponatremia, and orthostatic hypotension, which can worsen mental status in cirrhosis 8

The American College of Gastroenterology recommends extreme caution or avoidance of mirtazapine in decompensated cirrhosis with ascites, variceal bleeding, active hepatic encephalopathy, or jaundice, and avoidance of benzodiazepines entirely due to high risk of precipitating encephalopathy 8

The National Institute of Diabetes and Digestive and Kidney Diseases suggests that mirtazapine carries specific risks that require monitoring beyond hepatic encephalopathy, including somnolence, hyponatremia, and orthostatic hypotension, which can worsen mental status in cirrhosis, and recommends avoiding concomitant use with alcohol and benzodiazepines 8